

## Technology Advisory Committee B Interests Register

### ID3932 Belzutifan for treating tumours associated with von Hippel-Lindau disease

Publication Date: TBC.

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Interest ceased	Comments
Samra Turajlic	Clinical expert	Direct – financial	<p>Samara has previously participated in consultancy work with MSD</p> <p>Research funding: CRUK, NIH, US DOD, The Rosetrees Trust, VHL Alliance (US), Melanoma Research Alliance (US), RMH/ICR BRC, Francis Crick Institute, Roche, Arcobaleno Cancer Trust, Royal Marsden Cancer Charity</p> <p>Speaking/Advisory Fees - Clarivate, Erasmus, Open Health, MDAnderson, MSD, Merck, Ventana, Roche, IDEA Pharma Roche, Astra Zeneca, Novartis and Ipsen</p>		N/A	It was agreed that Samra's declaration would not prevent her from providing expert advice to the committee.

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Interest ceased	Comments
		Direct – non-financial	<p>Trustee Action Kidney Cancer, UK</p> <p>Published an opinion on systemic treatment of VHL disease (PMID: 26707870)</p>		N/A	It was agreed that Samra's declaration would not prevent her from providing expert advice to the committee.
Patrick Maxwell		Indirect – financial	<p>UKKA has received the following amounts; Novartis, £130k (research), Pfizer £2.4k (event sponsorship), and £175k (research)</p> <p>UK Kidney Association - has received the following amounts:</p> <p>Novartis:</p> <p>£130k - research</p> <p>Pfizer:</p> <p>£2.4k event sponsorship</p> <p>£175k - research</p>		N/A	It was agreed that Patrick's declaration would not prevent him from providing expert advice to the committee.

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Interest ceased	Comments
Dr Prithwiraj Das	TAC C Member	Non-Financial Professional	I work in life sciences, including pharmaceutical market access, as Founding Director of G2PR ltd. I have not worked on these products/indications in the last 12+ months.	15/02/2024	N/A	It was agreed that Prithwiraj's declaration would not prevent him from being on the committee.
Professor Eamonn Maher	Clinical expert	Direct – financial	Undertaken paid educational and consultancy work with MSD (manufacturers of belzultifan)	15/02/2024 24/10/2023	N/A	It was agreed that Professor Maher's declaration would not prevent him from providing expert advice to the committee.